Could a new PET tracer reveal hidden brain changes in dementia?
NCT ID NCT05384353
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a new radioactive tracer called [18F]-SynVesT-1 to measure brain synapse density in 134 people with Alzheimer's disease, frontotemporal degeneration, dementia with Lewy bodies, or late-life psychiatric disorders. Researchers compared this new scan to the standard FDG-PET scan to see which better distinguishes between these conditions. The goal was to understand how synapse loss relates to symptoms, not to provide a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]-SynVesT-1 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a better way to diagnose and understand different cognitive disorders by measuring brain synapse health.
What could go wrong
This is a completed observational study, not a treatment trial. The new tracer may not prove more useful than existing methods, and results may not change clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZ Leuven
Leuven, 3000, Belgium